


Convergent First Total Synthesis of Melovinsonone: A Densely Substituted 3-Methoxy-4-quinolone Isolated from *Melochia tomentosa* L.

Abel A. Arroyo Aguilar^aGabriela N. Ledesma^aBárbara Tirloni^bTeodoro S. Kaufman^{*a}Enrique L. Larghi^{*a}

^a Instituto de Química Rosario (QUIR, CONICET-UNR) and Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 531, 2000 Rosario, Argentina

larghi@iquir-conicet.gov.ar
kaufman@iquir-conicet.gov.ar

^b Departamento de Química, Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil



Received: 27.05.2019

Accepted after revision: 26.07.2019

Published online: 12.08.2019

DOI: 10.1055/s-0039-1690164; Art ID: ss-2019-m0298-op

Abstract The first total synthesis of melovinsonone, a nonrutaceous 3-methoxy-4-quinolone alkaloid isolated from *Melochia tomentosa* L., is reported. The target was acquired in a convergent fashion through the Suzuki–Miyaura cross-coupling reaction between an *ortho*-nitrobenzoic acid acetyl ester derivative prepared from vanillin and potassium 5-phenyl-1-pentyltrifluoroborate, obtained from β -phenethyl bromide. The coupling was followed by a chemoselective reduction of the nitro group and a microwave-assisted and AcOH-promoted cyclization with rearrangement of the resulting acetyl anthranilate. This afforded a pseudane intermediate, which was selectively methylated on the 3-OH. The synthetic pathway enabled to reach the objective in 11 steps and 18% overall yield. The ¹H NMR spectra of the synthetic and natural product were in full agreement.

Key words melovinsonone, total synthesis, natural products, nonrutaceous alkaloids, 3-methoxy-4-quinolones

During the last decades, a small family of bioactive 3-methoxy-4-quinolones has emerged; however, unlike the structurally related rutaceous alkaloids, its members display a pendant C-5 (ar)alkyl group or a seven-membered ring fused to C-5 and C-6, to form a cyclohepta[f]quinolone core, decorated with an unsaturation or oxygen functionalities.

The first examples (Figure 1) were melochinone (**1**),^{1a} and its plausible biogenetic precursor melovinsonone (**2**), isolated from the Colombian shrub *Melochia tomentosa* L. (Sterculiaceae).^{1b} Recently, the related waltheriones A (**3**)^{2a} and B (**4**)^{2b} were isolated from the root bark of *Waltheria douradinha* St.-Hil. Waltherione A was also isolated from *M. chamaedrys* A. St.-Hil, which grows in southern Brazil,^{3a} and from *M. odorata* L. f., harvested in New Caledonia.^{3b}

In addition, 5'-methoxywaltherione A (**5**) and helict-erone A (**6**) were obtained from the woody herb *Triumfetta*




Figure 1 Chemical structures of melovinsonone (**2**) and related 4-quinolones


grandidens^{4a–c} and from the Chinese tree *Helicteres angustifolia* L., respectively.^{4d} The waltheriones C (**7**) and D (**8**) were isolated from *M. odorata* collected in Papua New Guinea.^{4e} The family was enlarged with the isolation of the waltheriones E–Q and others⁵ from the roots of the Nigerian plant *Waltheria indica* L., most of which share the common core **9**.

Interestingly, the alkaloids **3**, **5**, and **7** inhibited the growth of various nematodes.^{4a–c} In addition, waltherione A (**3**) has broad-spectrum antifungal activity,^{3b} whereas compound **7** exhibited potent and selective activity against *Trypanosoma cruzi*,^{6a–c} and cytotoxicity against P-388 murine leukemia cells,^{4e,6a} being also cancer chemopreventive,^{6d} and cytoprotective against HIV infection.^{4e} Other waltheriones

also behaved as potent antifungal and cytotoxic agents.^{5b} The bioactivities of the extracts of *W. indica* L. have been recently reviewed.⁷

Constrastingly, few synthetic efforts to access these compounds have been recorded to date. These include a study toward **7**,^{8a} the elaboration of the oxabicyclic core of **7** and **8**,^{8b} and the total synthesis of waltherione F.^{8c,d}

We are interested in the synthesis of heterocyclic natural products⁹ and the development of analogues, to assess their structure and bioactivity profile.¹⁰ In pursuit of these interests, herein we disclose the first total synthesis of melovinone (**2**), based on the retrosynthetic analysis depicted in Scheme 1.



The initial disconnections of melovinone were carried out at the C-3 methyl ether, the aralkyl side chain and between the C-3–C-4 and N–C-2 bonds of the B-ring. These scissions were performed considering that a Niementowski reaction¹¹ could be a viable means toward the 3-hydroxyquinolone core, which could be further *O*-methylated at a later stage. On the other hand, the side chain was strategically dissected, having in mind a cross-coupling reaction between a properly substituted ω -phenylpentyl derivative **10** and an activated benzenoid. These speculations revealed the anthranilate acetonide **11** as a suitable precursor.


In turn, **10** was disconnected into the β -phenethyl derivative **12** and the allyl component **13**, under the conjecture that the ω -phenylpentyl moiety could result from the alkylation of an activated form of β -phenethyl halide **12** and a three-carbon atoms species like **13**. An additional disconnection was also performed on the ester moiety of **11**, unveiling an *ortho*-halobenzaldehyde derivative as its proper precursor, on the assumption that the haloarene could be

a successful scaffold to install the aralkyl side chain, whereas the acetonide could be easily accessible from the formyl group and an activated acetone equivalent **14**.

Further, it was inferred that the amine feature of the key anthranilate could result from a nitro group, through functional group interconversion. Therefore, the 2-nitrobenzaldehyde derivative **15** was assumed as a convenient forerunner of **11**. This approach offered the possibility to perform a convergent synthesis of the natural product by joining **10** and **11**, as well as a stepwise alternative, which should entail coupling **11** to **13** and then react their coupling product with a species like **12**.

Additional simplifications were performed on **15**, by disconnecting both substituents *ortho* to the formyl moiety, under the premise that the directing effects of the different functional groups will enable the selective functionalization of the aromatic ring. These thoughts uncovered the economical and easily available vanillin (**16**) as a logical starting point.

With the above strategy in mind, the synthesis of **2** began with the acetylation of vanillin (required to avoid *ortho*-phenol bromination)¹² under conventional conditions (Ac₂O, DMAP), to give **17** in 93% yield (Scheme 2). Without purification, this material was subjected to bromination with Br₂ and KBr in MeCN/H₂O,¹³ providing the bromoarene **18** in almost quantitative yield. Next, basic hydrolysis of the acetate **18** furnished the intermediate **19** (85% yield), which was submitted to a Williamson *O*-methylation with MeI in MeCN, employing Cs₂CO₃ as base, to afford the veratraldehyde derivative **20** in 72% overall yield from **18**.



Scheme 2 Reagents and conditions: a) Ac₂O, DMAP, 40 °C, 2 h (93%); b) Br₂, KBr, MeCN/H₂O (1:1 v/v), rt 12 h (95%); c) aq 3 M NaOH, rt (85%); d) MeI, Cs₂CO₃, MeCN, reflux, 5 h (85%); e) HNO₃ (d = 1.52 g·cm⁻³), 0–6 °C, 10 min (polynitrated products); f) HNO₃ (d = 1.52 g·cm⁻³), 0–6 °C, 10 min (99%); g) aq 0.5 M KOH, 1,4-dioxane, 40 °C, 1 h (81% from **18**); h) MeI, K₂CO₃, DMF, 50 °C 5 h (91%); i) CrO₃, H₂SO₄, acetone, 0 °C → rt, 1 h (99%); j) 1. K₂CO₃, DMF, 40 °C, 1 h; 2. ClCH₂C(O)Me, DMF, 20–50 °C, 1 h (99%).

The subsequent step involved installation of the nitro moiety; however, when nitration of **20** was carried out with red fuming nitric acid, only polynitrated materials were observed and **21** could not be detected. Other nitration conditions such as mixtures of HNO₃ with H₂SO₄, AcOH and Ac₂O were also tested, but all of them met with failure.

Conjecturing that the acetate **18** should be a less reactive substrate than the related methyl ether **20**,^{14a,b} the nitration of the former with fuming HNO₃ was explored, observing the exclusive formation of the desired nitro derivative **22** in 99% yield. Then, the acetate was hydrolyzed with KOH in 1,4-dioxane and the resulting phenol **23** was methylated, providing the benzaldehyde **21** in 81% overall yield from **18**.^{14c,d}

Next, the benzaldehyde **21** was conveniently oxidized with Jones' reagent to the related benzoic acid **24** in 99% yield. The proper aromatic substitution pattern of **24** was assessed by NMR spectroscopy and the molecular structure was also confirmed by single crystal X-ray diffraction (Figure 2).¹⁵





Figure 2 Molecular structure of **24**. The displacement ellipsoids were drawn at the 50% probability level and hydrogen atoms were omitted for the sake of clarity, excepting the OH group.


Without additional purification, the acid **24** was treated with chloroacetone and K₂CO₃ in DMF, to give the acetonylester **25** in 99% yield, setting the stage for the installation of the C-5 side chain. A Suzuki–Miyaura strategy was chosen to fulfil the task, because this is a leading methodology which tolerates a broad range of functional groups and is increasingly used to create new Csp³–Csp² bonds.¹⁶

Among different alternatives, the synthesis of the trifluoroborate salt **30** as the boron component was next undertaken, through the intermediacy of 5-phenyl-1-pentene (**28**). Therefore, β-phenethyl bromide (**26**) was exposed to Mg⁰ in Et₂O to give the Grignard reagent **27**, and this was made to react with allyl bromide to afford **28** in 95% yield (Scheme 3).¹⁷



Scheme 3 Reagents and conditions: a) Mg⁰, I₂, Et₂O, rt; b) BrCH₂CH=CH₂, Et₂O, 15 °C, 1 h (95% from **26**); c) 1. 1.4 M BH₃·SMe₂ in toluene, CCl₄, 0 °C, 30 min. Then rt, 3 h; 2. aq 2 M HCl, H₂O, rt (83%); d) sat. aq KHF₂, MeOH, rt, 3 h (22%).

Then, the terminal alkene was submitted to a hydroboration with excess BH₃·SMe₂ in CCl₄,^{18a} to afford 83% yield of the alkylboronic acid intermediate **29** after acid hydrolysis.^{18b} Final treatment of the latter with KHF₂ in MeOH, gave the required potassium 5-phenyl-1-pentyltrifluoroborate (**30**).¹⁹ The Suzuki–Miyaura reaction of **30** with the bromoarene **25** was executed in the presence of the hindered phosphine ligand di-*tert*-butyl phosphinoferrrocene (dtbpf) to minimize competitive β-hydride elimination.²⁰ The transformation proceeded smoothly to afford the cross-coupled product **31** in 93% yield (Scheme 4), accompanied by 5% of the debrominated compound **32**.



Scheme 4 Reagents and conditions: a) Ph(CH₂)₅BF₃K (**30**), Pd(AcO)₂, dtbpf, K₂CO₃, toluene/H₂O (10:1), 80 °C 18 h (**31**, 93%; **32**, 5%); b) Ni₂B, H₂ (1 atm), 1 M HCl, MeOH, 70 °C, 30 min (81%); c) glacial AcOH, MW (150 °C, 60 W), 25 min; d) MeI, *i*-PrOH, K₂CO₃, 50 °C, 3.5 h (40%, from **33**).


Construction of the heterocyclic B-ring was subsequently undertaken. Hence, the reduction of the nitro group of **31** was pursued, with freshly prepared nickel boride in MeOH, gently affording the acetonylester anthranilate **33** in 81% isolated yield.²¹

Then, the latter was submitted to an intramolecular Niementowski cyclization/rearrangement protocol,²² involving the microwave irradiation (150 °C, 60 W) of a dilute solution of the ester in glacial AcOH.

Formation of the sought pseudane key intermediate **34** took place smoothly, as first evidenced during TLC monitoring of the reaction, where the heterocycle exhibited a characteristic fluorescence when irradiated with long wavelength (365 nm) UV-light and a blue colored spot, when the plate was sprayed with a FeCl_3 solution.

Various alternative mechanisms have been suggested for the classical Niementowski quinoline synthesis, all of which involve N-C-2 and C-3-C-4 bond formation in different order.²³

Although the actual sequence of transformations leading to **34** remains unknown, a mechanistic picture can be proposed on the basis of analogous processes^{22b,c} (Scheme 5). The reaction could be initiated by protonation of the ketone moiety of **33** and intramolecular nucleophilic attack by the amino group on the protonated carbonyl **i** to afford a 1,4 oxazepin-5(1*H*)-one derivative **ii** after dehydrative cyclization.



Scheme 5 Proposed mechanism for the Niementowski type cyclization/rearrangement of **33** toward **34**


Subsequent formation of the oxa-azabicyclo[4.1.0]heptadiene-type intermediate **iii** by intramolecular attack of the enamine motif to the ester carbonyl under the assistance of the free electronic pair of the nitrogen, could be followed by rearrangement with concomitant oxirane ring opening to the α -hydroxyketonic intermediate **iv**, which in turn could undergo a 1,3-proton shift to afford **34**.

The chromatographic purification of **34** proved troublesome.²⁴ Therefore, the crude material was carried forward to the final methylation step (Scheme 4). Based on our experience on the selective alkylation of quinolones,^{8c,25} **34** was treated with MeI and K_2CO_3 in anhydrous *i*-PrOH, and the system was refluxed in a closed vessel for 3.5 hours, to give 40% of melovinsonone (**2**). Delightfully its ^1H NMR spectrum was in full agreement with that of the natural product.^{1b}

Additional confirmation of the suitability of the Suzuki-Miyaura approach for the key step of joining of the ω -phen-

ylpentyl side chain to the polysubstituted aromatic core **39** was obtained after developing and testing alternative strategies based on other proven cross-coupling schemes, such as the Sonogashira and Stille reactions.

In the first case, the model **35** was prepared by joining **25** with 1-octyne; however, the reaction product demonstrated to be too unstable for further manipulation and had to be abandoned (Scheme 6). On the other hand, in the Stille-based strategy, it was expected to convert **25** into the allylbenzene derivative **36**, which after olefin cross-metathesis with 4-phenyl-1-butene (**38**) should provide the proper intermediate **39**. Therefore, as planned the bromoarene **25** was submitted to Stille cross-coupling conditions with allyltributyltin in toluene under $\text{Pd}(\text{Ph}_3\text{P})_4$ catalysis, affording the allylbenzenoid **36** in 92% yield.



Sadly enough, however, compound **36** proved to be too labile, easily suffering partial isomerization to the related β -methylstyrenes **37**. It was further observed that the reaction was promoted by the acidity of the silica gel during the chromatographic purification step, as well as by the residual acidity of the CDCl_3 , as assessed when running long NMR experiments in this solvent. These undesired by-products were also detected when the Stille reaction was allowed to proceed during extended periods of time, and its facile formation was attributed to the presence of the electron-withdrawing groups in **36**.²⁶

In an attempt to solve this drawback, the crude compound **36** was carried to the next stage, the cross-metathesis reaction with 4-phenyl-1-butene (**38**).²⁷ However, TLC monitoring of the reaction revealed a complex series of spots, corresponding to compounds, which could not be separated chromatographically. The mixture was examined by ^1H and ^{13}C NMR spectroscopy, concluding that its components included the desired product **39**, and the

corresponding lower homologue **40** (53% combined yield). Furthermore, both compounds (**39:40** = 1.8:1) were present as mixtures of their geometric isomers, complicating the analysis and their separation. Presumably, compound **40** arose from the cross-coupling reaction between **38** and the β -methylstyrenes **37**.

Several experiments were carried out with the aim to suppress this undesired reaction. These included changing the catalyst (from Grubbs II to Hoveyda–Grubbs II)^{28a} and solvent (from toluene to CH₂Cl₂), as well as adding 1,4-benzoquinone to inhibit the isomerization reaction.^{28b,c} In addition, a ‘two-steps one-pot’ Stille–Grubbs protocol was also explored.²⁹ However, no significant improvements were observed.

In conclusion, the first total synthesis of the nonruteaceous alkaloid melovine was accomplished on 11 steps and 18% overall yield from commercially available vanillin, α -chloroacetone and β -phenethyl bromide, by means of a convergent strategy, with minimum use of protecting groups.

The sequence toward the natural product entailed the preparation of the key 2-nitro-3,4-dimethoxy-6-bromobenzoic acid acetyl ester, and its subsequent cross-coupling under Suzuki–Miyaura conditions, with potassium 5-phenylpentyl trifluoroborate and palladium catalysis, with dtbpf as ligand.

Building of the heterocyclic ring was accomplished by the chemoselective nitro group reduction with Ni₂B, a microwave-promoted cyclization of the so formed acetyl anthranilate and final methylation of the 3-OH moiety of the resulting pseudane.

The convergent approach to access melovine employing a Suzuki–Miyaura cross-coupling proved to be a highly suitable alternative toward the total synthesis of the natural product. It paves the route toward acquisition of more complex targets and may find application in the synthesis of other members of this family of heterocycles, such as the polycyclic waltheriones.

All the reactions were carried out under dry N₂ or argon atmospheres, employing oven-dried glassware. Anhyd THF was obtained from a M. Braun solvent purification and dispenser system; anhyd DMF was obtained by heating the PA grade product over BaO for 4 h, followed by distillation under reduced pressure; anhyd toluene, THF, and Et₂O were distilled from blue Na⁰/benzophenone ketyl; anhyd Et₃N was prepared by distillation of the commercial product from CaH₂; anhyd MeOH and 2-propanol were prepared by distillation after refluxing the solvent for 24 h over I₂-activated Mg⁰ turnings; anhydrous solvents were stored in dry Young ampoules.³⁰ EtOH refers to the 96° product. All other solvents and reagents were used as received.

Flash chromatographies were carried with silica gel 60 H (particle size <55 μ m). Elution of the compounds was carried out with hexanes/EtOAc or EtOAc/EtOH mixtures, under positive pressure and

employing gradient of solvent polarity techniques. All new compounds gave single spots on TLC plates run in different hexane/EtOAc and EtOAc/EtOH solvent systems.

The chromatographic spots were detected by exposure to 254 and 365 nm UV light, followed by spraying with Dragendorff reagent (Munier and Macheboeuf modification),³¹ with FeCl₃ 2.5% in H₂O (to detect pseudane like molecules) or with ethanolic *p*-anisaldehyde/H₂SO₄ reagent and final careful heating of the plates for improving selectivity.

The melting points were measured on an Ernst Leitz Wetzlar model 350 hot-stage microscope and are uncorrected. The FT-IR spectra were acquired on a Shimadzu Prestige 21 spectrophotometer, with the samples prepared as solid dispersions in KBr disks or as thin films held between NaCl cells. The NMR spectra were acquired at 300.13 MHz (¹H), 75.48 MHz (¹³C) MHz, 96.29 MHz (¹¹B) and 282.38 MHz (¹⁹F) on a Bruker Avance 300 spectrometer in CDCl₃ as solvent, unless stated otherwise. The residual resonance of CHCl₃ in CDCl₃ (δ_{ref} ¹H = 7.26), BF₃·OEt₂ (δ_{ref} ¹¹B = 0.00) as well as the signals of CDCl₃ (δ_{ref} ¹³C = 77.16) and CFCl₃ for (δ_{ref} ¹⁹F = 0.00) were used as the corresponding standards. Chemical shifts are reported in parts per million in the δ scale and *J*-values are given in hertz (Hz). In special cases, NOE and 2D-NMR experiments (COSY, HMBC and HMQC) were also employed. Pairs of signals marked with an asterisk or hash signs (* or #) indicate that their assignments may be exchanged. Samples for NMR spectra were dissolved in CDCl₃ unless otherwise stated. The high-resolution mass spectra were obtained with a Bruker microTOF-Q IIT instrument (Bruker Daltonics, Billerica, MA) employing sodium formate as reference. Detection of the ions was performed in electrospray ionization, positive ion mode unless otherwise stated.

For single-crystal structure determination the data were collected with a Bruker D8 Venture diffractometer. The equipment was operated using a graphite monochromator with Mo-K α radiation (λ = 0.71073 Å). The structure was solved by direct methods using SHELXS and refined with SHELXL on F² using anisotropic temperature parameters for all non-hydrogen atoms.³² The positions of the hydrogen atoms were calculated starting from the idealized positions. Microwave-assisted reactions were performed in a CEM Discover microwave oven.

4-Acetoxy-3-methoxybenzaldehyde (Acetylvanillin, **17**)

A solution of vanillin (**16**; 4.0 g, 26.29 mmol) and DMAP (22 mg, 0.180 mmol) in Ac₂O (5 mL) was heated at 40 °C during 2 h with vigorous stirring. After verifying complete consumption of the starting material, the mixture was poured over crushed ice (30 g). The resulting white precipitate was recovered by filtration and washed with H₂O (3 \times 100 mL). This solid material was dissolved in EtOAc (50 mL), the organic solution was successively washed with H₂O (2 \times 50 mL) and brine (2 \times 50 mL), dried (MgSO₄) and concentrated to afford **17** as a white solid; yield: 4.8 g (93%).

¹H NMR (300 MHz, CDCl₃): δ = 9.94 (s, 1 H, CHO), 7.51 (d, *J* = 1.8 Hz, 1 H, H-2), 7.49 (dd, *J* = 7.8, 1.8 Hz, 1 H, H-6), 7.21 (d, *J* = 7.8 Hz, 1 H, H-5), 3.89 (s, 3 H, 3-OCH₃), 2.34 (s, 3 H, 2'-CH₃).

¹³C NMR (75 MHz, CDCl₃): δ = 191.2 (CHO), 168.5 (1'-CO₂), 152.1 (C-3), 145.1 (C-4), 135.4 (C-1), 124.9 (C-5), 123.5 (C-6), 111.0 (C-2), 56.2 (3-OCH₃), 20.8 (2'-CH₃).

These data were in accordance with the literature values.³³

4-Acetoxy-6-bromo-3-methoxybenzaldehyde (**18**)

Br₂ (9.52 g, 59.9 mmol) was cautiously dropped into a solution of **17** (3.90 g, 19.9 mmol) and KBr (8.03 g, 67.5 mmol) in MeCN/H₂O (1:1, v/v, 150 mL). The system was firmly closed and stirred for 20 h at rt, when complete consumption of the starting material was assessed. Then, the mixture was poured onto crushed ice (100 g), the solids were filtered, washed with H₂O, and further dissolved in EtOAc (300 mL). The organic solution was washed with H₂O (250 mL) and brine (2 × 100 mL), and dried (MgSO₄). The volatiles were removed in vacuo to afford **18** as an orange solid; yield: 5.13 g (95%).

¹H NMR (300 MHz, CDCl₃): δ = 10.27 (s, 1 H, CHO), 7.51 (s, 1 H, H-2), 7.36 (s, 1 H, H-5), 3.89 (s, 3 H, 3-OCH₃), 2.33 (s, 3 H, 2'-CH₃).

¹³C NMR (75 MHz, CDCl₃): δ = 191.0 (CHO), 168.1 (1'-CO₂), 151.4 (C-3), 145.1 (C-4), 131.7 (C-1), 128.1 (C-5), 118.0 (C-6), 112.3 (C-2), 56.4 (3-OCH₃), 20.7 (2'-CH₃).

These data were in accordance with the literature values.³³

4-Acetoxy-6-bromo-3-methoxy-2-nitrobenzaldehyde (**22**)

The solid acetate **18** (524 mg, 1.92 mmol) was gradually added in small portions over a period of 10 min and under vigorous stirring to concd red fuming HNO₃ (d = 1.52 g·cm⁻³, 1.9 mL) kept at 0–6 °C. Once the addition was finished and the dissolution of the solid was visually complete, the mixture was poured onto crushed ice (50 g). When the ice melted, the products were extracted with Et₂O (3 × 20 mL), and the combined organic phases were washed with brine (30 mL) and dried (MgSO₄). After removal of the volatiles under reduced pressure, the nitro derivative **22** was obtained as a bright yellow amorphous solid; yield: 613 mg (99%).

¹H NMR (300 MHz, CDCl₃): δ = 10.19 (s, 1 H, CHO), 7.63 (s, 1 H, H-5), 3.91 (s, 3 H, 3-OCH₃), 2.39 (s, 3 H, 2'-CH₃).

¹³C NMR (75 MHz, CDCl₃): δ = 187.4 (CHO), 167.2 (1'-CO₂), 148.9 (C-4), 145.1 (C-2), 144.2 (C-3), 130.6 (C-5), 123.0 (C-1), 120.6 (C-6), 63.2 (3-OCH₃), 20.9 (2'-CH₃).

These data were in accordance with the literature values.³⁴

6-Bromo-4-hydroxy-3-methoxy-2-nitrobenzaldehyde (**23**)

Method A: The acetate **22** (600 mg, 1.88 mmol) was suspended in aq 3 M NaOH (10 mL). The system was heated at 40 °C for 1 h with vigorous stirring under a N₂ atmosphere. Once complete hydrolysis was confirmed by TLC, the aqueous solution was washed with Et₂O (2 × 5.0 mL), then made acidic with aq 6 M HCl (ca. 5 mL), and the products were extracted with Et₂O (3 × 50 mL). The combined organic phases were washed with brine (25 mL), dried (MgSO₄), and concentrated under vacuum. The desired phenol **23** was obtained as a pale brownish solid; yield: 448 mg (86%).

¹H NMR (300 MHz, acetone-*d*₆): δ = 10.09 (s, 1 H, CHO), 7.46 (s, 1 H, H-5), 3.94 (s, 3 H, 3-OCH₃).

¹³C NMR (75 MHz, acetone-*d*₆): δ = 188.1 (CHO), 158.3 (C-4), 146.3 (C-2), 140.7 (C-3), 123.2 (C-5), 123.1 (C-6), 117.7 (C-1), 62.6 (3-OCH₃).

The spectroscopic data were in agreement with the literature.³⁴

Method B: The bromoacetate **18** (2.98 g, 10.95 mmol) was portionwise added to concd red fuming HNO₃ (d = 1.52 g·cm⁻³, 1.9 mL) at 0–6 °C during a period of 10 min under vigorous stirring. Once the addition was finished and dissolution of the solid was complete, the bright yellow solution was poured onto crushed ice (100 g). The product was extracted with Et₂O (3 × 250 mL), washed with brine (30 mL), and dried (MgSO₄). After removal of the volatiles, the thus obtained solid nitro derivative was treated with aq 0.5 M KOH (150 mL) and

heated at 40 °C during 1 h. Once saponification was completed, the mixture was driven to pH ~1 by addition of aq 6 M HCl (50 mL) and the aqueous phase was extracted with Et₂O (3 × 150 mL), the combined organic phases were washed with brine (30 mL), and dried (MgSO₄). Removal of the solvent afforded the free phenol **23** as a pale brown solid; yield: 2.40 g (81%). The ¹H NMR spectrum was in agreement with that of the solid obtained by application of Method A.

6-Bromo-3,4-dimethoxy-2-nitrobenzaldehyde (**21**)

The phenol **23** (2.2 g, 8.03 mmol) was dissolved in anhyd DMF (25 mL) and the solution was sequentially treated with K₂CO₃ (2.2 g, 16.1 mmol) and MeI (2.5 mL, 40.0 mmol). The resulting slurry was heated at 50 °C for 5 h under N₂ atmosphere. Once complete consumption of the starting material was assessed, the solids were filtered off, and the remaining DMF solution was diluted with H₂O (100 mL). The products were extracted with Et₂O (3 × 50 mL), the combined organic phases were washed with aq 3 M NaOH (2 × 25 mL), H₂O (3 × 30 mL) and brine (30 mL), and dried (MgSO₄). After filtration and concentration under reduced pressure, the veratraldehyde derivative **21** was obtained as a yellow oil; yield: 2.12 g (91%).

¹H NMR (300 MHz, CDCl₃): δ = 10.12 (s, 1 H, CHO), 7.23 (s, 3 H, H-5), 4.02 (s, 3 H, 4-OCH₃), 3.91 (s, 3 H, 3-OCH₃).

¹³C NMR (75 MHz, CDCl₃): δ = 187.5 (CHO), 158.6 (C-4), 145.1 (C-2), 141.1 (C-3), 123.1 (C-1),* 118.0 (C-5), 117.6 (C-6),* 62.3 (3-OCH₃), 57.1 (4-OCH₃).

The ¹H NMR data were in accordance with the literature.^{14c}

6-Bromo-3,4-dimethoxy-2-nitrobenzoic Acid (**24**)

A solution of the veratraldehyde derivative **23** (1.93 g, 6.80 mmol) in acetone (50 mL) was cooled to 0 °C (ice bath) and Jones reagent (2.0 mL) was slowly added dropwise. The system was warmed to rt and stirred for 1 h until the starting aldehyde was fully consumed. Then, 2-propanol was added in order to quench the excess of reagent, the solvent was cautiously removed under vacuum, the remaining suspension was treated with sat. aq Na₂CO₃ (5 mL) and extracted with Et₂O (3 × 50 mL). The organic phase was washed with brine (2 × 50 mL), dried (MgSO₄) and the volatiles evaporated to give the benzoic acid derivative **24** as a yellowish solid; yield: 2.0 g (99%); mp 197–195 °C (from CHCl₃/MeOH 9:1, v/v) (Lit.^{14d} mp 199–198 °C (dil EtOH)).

¹H NMR (300 MHz, acetone-*d*₆): δ = 7.56 (s, 1 H, H-5), 4.07 (s, 3 H, 4-OCH₃), 3.94 (s, 3 H, 3-OCH₃).

¹³C NMR (75 MHz, acetone-*d*₆): δ = 164.3 (CO₂H), 155.8 (C-4), 146.3 (C-2), 141.5 (C-3), 121.6 (C-1), 120.3 (C-5), 115.5 (C-6), 63.2 (3-OCH₃), 57.9 (4-OCH₃).

Single crystals suitable for X-ray analysis were obtained after slow solvent evaporation from a CHCl₃/MeOH (9:1, v/v) solution.¹⁵

2'-Oxopropyl 6-Bromo-3,4-dimethoxy-2-nitrobenzoate (**25**)

The benzoic acid **24** (500 mg, 1.63 mmol) was dissolved in anhyd DMF (5.0 mL) and treated with anhyd K₂CO₃ (293 mg, 2.12 mmol). The system was heated at 40 °C for 1 h under argon, and treated with freshly distilled α-chloroacetone (328 μL, 4.08 mmol) at 20 °C, over a 30 min period. The slurry was heated at 50 °C during additional 30 min, when it was poured onto crushed ice (10 g) and left during 10 min. The products were extracted with EtOAc (3 × 25 mL), the combined organic phases were washed with brine (20 mL), dried (MgSO₄) and concentrated to dryness. The brownish oil obtained was chromatographed to afford the acetyl ester **25** as a brownish solid; yield: 585 mg (99%); mp 71–73 °C (from hexanes/EtOAc 1:1, v/v).

IR (KBr): 2922, 2854, 1751, 1724, 1616, 1548, 1420, 1375, 1281, 1148, 1043, 718 cm^{-1} .

^1H NMR (300 MHz, CDCl_3): δ = 7.26 (s, 1 H, H-5), 4.78 (s, 2 H, H-1'), 3.97 (s, 3 H, 4-OCH₃), 3.95 (s, 3 H, 3-OCH₃), 2.23 (s, 3 H, 3'-CH₃).

^{13}C NMR (75 MHz, CDCl_3): δ = 201.0 (C-2'), 162.4 (ArCO₂CH₂), 156.0 (C-4), 145.9 (C-2), 141.7 (C-3), 119.4 (C-1), 119.1 (C-5), 116.3 (C-6), 69.9 (C-1'), 62.5 (3-OCH₃), 57.3 (4-OCH₃), 26.6 (3'-CH₃).

HRMS (ESI): m/z [M + Na]⁺ calcd for C₁₂H₁₂BrNO₇Na: 383.9689; found: 383.9682.

Potassium 5-Phenyl-1-pentyltrifluoroborate (30)

A solution of 2-phenyl-1-bromoethane (**26**; 2.07 mL, 15.1 mmol) in anhyd Et₂O (6.0 mL) was transferred to an addition funnel and slowly added to a stirred suspension of Mg⁰ (405 mg, 16.5 mmol) in Et₂O (2.0 mL) containing a crystal of I₂ under argon. The reaction was initiated by addition of an ethereal solution of phenethyl bromide (0.5 mL), which caused the system to reflux; this condition was kept by continuous dropping of the phenethyl bromide solution. Once the addition was completed, the system was heated to reflux for an additional 1 h period. Then, the reaction system was allowed to cool to rt, placed in a cooled water-bath at 15 °C and the Grignard reagent **27** was treated dropwise during 1 h with a recently distilled solution of allyl bromide (1.8 mL, 15.2 mmol) in anhyd Et₂O (6.0 mL). After this, sat. aq NH₄Cl (5.0 mL) was cautiously added to quench the reaction, and the aqueous phase was extracted with Et₂O (3 × 5.0 mL). The combined organic phases were dried (MgSO₄), the volatiles were evaporated off under reduced pressure to afford 5-phenyl-1-pentene **28** as an oily residue; yield: 2.36 g (95%).

^1H NMR (300 MHz, CDCl_3): δ = 7.31–7.14 (m, 5 H), 5.83 (ddt, J = 16.9, 10.2, 6.6 Hz, 1 H, H-1), 5.06–4.95 (m, 2 H, H-2), 2.62 (t, J = 7.7 Hz, 2 H, H-5), 2.13–2.06 (m, 2 H, H-3), 1.77–1.67 (m, 2 H, H-4).

^{13}C NMR (75 MHz, CDCl_3): δ = 142.6 (C_{ipso}), 138.8 (C-2), 128.6 (2 C, C_{ortho}), 128.4 (2 C, C_{meta}), 125.8 (C_{para}), 114.8 (C-1), 35.5 (C-5), 33.4 (C-3), 30.8 (C-4).

These data were in accordance with the literature,^{17a} and the crude material was used in the next step without further purification.

A recently titrated solution of BH₃·SMe₂ (1.4 M in toluene, 3.2 mL, 4.45 mmol) dissolved in anhyd CCl₄ (5.0 mL) at 0 °C was treated dropwise during 30 min with a solution of alkene **28** (500 mg, 3.42 mmol) in CCl₄ (10 mL), while the diborane evolving from the reaction was quenched by bubbling in an acetone/H₂O solution. Once the addition was completed, the reaction was warmed to rt, and stirred under an argon atmosphere during an additional 3 h period, when the thus formed alkylboranes were cautiously hydrolyzed at 0 °C by dropwise addition of a solution of MeOH (2.0 mL) in CH₂Cl₂ (5.0 mL) over 30 min. Once the gas evolution ceased, aq 2 N HCl (3.42 mL) was added in order to complete the boronic acid formation.^{20b} The organic phase was separated, washed with sat. aq NaHCO₃ (5.0 mL) and brine (5.0 mL), dried (Na₂SO₄), and concentrated under reduced pressure until dryness, to afford the crude boronic acid intermediate **29**; yield: 549 mg (83%). This material (549 mg, 2.84 mmol) was dissolved in MeOH (6.0 mL) and reacted with sat. aq KHF₂ (4.3 mL) at rt during 3 h. The volatiles were removed under vacuum to give a whitish solid material, which was extracted with hot acetone (4 × 5.0 mL). Evaporation of the solvent furnished the desired potassium salt **30** as a white solid; yield: 161.2 mg (22%); mp >200 °C (from acetone).

IR (NaCl): 2922, 2853, 1300, 1082, 1058, 1031, 959, 741, 696 cm^{-1} .

^1H NMR (300 MHz, acetone-*d*₆): δ = 7.26–7.10 (m, 5 H, C₆H₅), 2.56 (t, J = 7.8 Hz, 2 H, H-5), 1.62–1.51 (m, 2 H, H-4), 1.32–1.27 (m, 4 H, H-2, H-3), 0.17–0.14 (m, 2 H, H-1).

^{13}C NMR (75 MHz, acetone-*d*₆): δ = 144.1 (C_{ipso}), 129.1 (2 C, C_{ortho}), 128.9 (2 C, C_{meta}), 126.2 (C_{para}), 36.8 (C-5), 34.1 (C-4), 32.9 (C-3), 26.2 (C-2). Note: the C-1 peak could not be observed in the ^{13}C NMR spectrum.

^{19}F NMR (282 MHz, acetone-*d*₆): δ = -141.1.

^{11}B NMR (96 MHz, acetone-*d*₆): δ = 5.7.

HRMS (ESI, negative mode): m/z [M]⁻ calcd for C₁₂H₁₈BO₂: 205.1400, found: 205.1390. The mass corresponds to the *O*-monomethylboronate anion, resulting from solvolysis of **30** in the MeOH/HCO₂NH₄ medium used for HRMS sample dissolution.

2'-Oxopropyl 3,4-Dimethoxy-2-nitro-6-(5-phenylpentyl)benzoate (31) and 2'-Oxopropyl 3,4-Dimethoxy-2-nitrobenzoate (32)

A slurry composed by 2'-oxopropyl 6-bromo-3-methoxy-2-nitrobenzoate (**25**; 80 mg, 0.22 mmol), potassium 5-phenyl-1-pentyltrifluoroborate (**30**; 89.8 mg, 0.35 mmol), K₂CO₃ (91.5 mg, 0.66 mmol), Pd(OAc)₂ (2.0 mg, 0.009 mmol), and dtbpf (6.3 mg, 0.013 mmol) in toluene (2.4 mL) was purged with argon for 5 min. Freshly distilled H₂O (200 μL , 0.011 mmol) was added, the tube was closed, and the system was heated to 80 °C during 18 h. Once assessed that the starting arene was fully consumed, the mixture was diluted with H₂O (5 mL) and extracted with Et₂O (3 × 30 mL). The organic phase was washed with aq 1 M HCl (10 mL), brine (20 mL), and dried (MgSO₄). The volatiles were removed in vacuo and the remaining oily material was chromatographed to afford the desired coupled product **31** as a yellowish oil; yield: 120 mg (93%).

IR (NaCl): 3024, 2932, 2855, 1738, 1730, 1608, 1537, 1454, 1371, 1281, 1157, 1047, 700 cm^{-1} .

^1H NMR (300 MHz, CDCl_3): δ = 7.30–7.16 (m, 5 H, C₆H₅), 6.84 (s, 1 H, H-5), 4.74 (s, 2 H, H-1'), 3.93 (s, 3 H, 4-OCH₃), 3.92 (s, 3 H, 3-OCH₃), 2.85–2.80 (m, 2 H, H-1''), 2.62 (td, J = 7.9, 2.6 Hz, 2 H, H-5''), 2.18 (s, 3 H, C-3'), 1.71–1.58 (m, 4 H, H-2'', H-4''), 1.47–1.38 (m, 2 H, H-3'').

^{13}C NMR (75 MHz, CDCl_3): δ = 200.7 (C-2'), 163.7 (ArCO₂CH₂), 155.3 (C-4), 145.8 (C-2), 142.6 (C_{ipso}), 140.9 (C-6), 139.5 (C-3), 128.4 (2 C, C_{ortho}),[#] 128.2 (2 C, C_{meta}),[#] 125.6 (C_{para}), 116.3 (C-1), 115.3 (C-5), 69.3 (C-1'), 62.3 (3-OCH₃), 56.4 (4-OCH₃), 35.8 (C-5''), 33.9 (C-1''), 31.8 (C-2''), 31.2 (C-4''), 29.1 (C-3''), 26.1 (C-3').

HRMS (ESI): m/z [M + Na]⁺ calcd for C₂₃H₂₇NO₇Na: 452.1680; found: 452.1677.

Increasing solvent polarity gave the proto-debrominated benzoate **32** as a colorless solid; yield: 3.3 mg (5%); mp 87–89 °C (from hexanes/EtOAc 3:7, v/v).

IR (KBr): 2943, 2851, 1741, 1724, 1616, 1541, 1458, 1284, 1150, 1043, 893, 740 cm^{-1} .

^1H NMR (300 MHz, CDCl_3): δ = 7.87 (d, J = 8.8 Hz, 1 H, H-6), 7.03 (d, J = 8.8 Hz, 1 H, H-5), 4.80 (s, 2 H, H-1''), 3.99 (s, 3 H, 3-OCH₃), 3.92 (s, 3 H, 4-OCH₃), 2.19 (s, 3 H, 3'-CH₃).

^{13}C NMR (75 MHz, CDCl_3): δ = 201.1 (C-2'), 162.0 (ArCO₂CH₂), 157.9 (C-3), 146.5 (C-2), 141.3 (C-4), 127.7 (C-6), 144.0 (C-1), 112.6 (C-5), 69.3 (C-1'), 62.7 (3-OCH₃), 57.2 (4-OCH₃), 26.3 (C-3').

HRMS (ESI): m/z [M + Na]⁺ calcd for C₁₂H₁₃NO₇Na: 306.5084; found: 306.5090.

2'-Oxopropyl 2-Amino-3,4-dimethoxy-6-(5-phenylpentyl)benzoate (33)

A mixture of **31** (40.0 mg, 0.093 mmol) and freshly prepared Ni₂B (35.8 mg, 0.279 mmol) in anhyd MeOH (1.3 mL) was stirred while a vigorous stream of H₂ was bubbled in during 5 min. The reaction

mixture was treated with aq 1 M HCl (310 μ L, 0.31 mmol), and the reaction tube was tightly closed and placed in a pre-heated bath at 70 °C for 30 min. After confirming the complete consumption of the starting material, a 0.4% aq solution of NaHCO₃ (5.0 mL) was added and the products were extracted with EtOAc (3 \times 10 mL). The combined organic phases were washed with brine (10 mL), dried (MgSO₄), and concentrated under reduced pressure to afford the acetonil anthranilate **33**, which was used in the next step without further purification; yield: 30 mg (81%).

IR (NaCl): 3491, 3377, 3024, 2928, 2851, 1717, 1599, 1452, 1369, 1265, 1139, 1043, 804, 737 cm⁻¹.

¹H NMR (300 MHz, CDCl₃): δ = 7.30–7.16 (m, 5 H, C₆H₅), 6.15 (s, 1 H, H-5), 5.50 (br s, $w_{1/2}$ = ~12.5 Hz, 2 H, NH₂), 4.86 (s, 2 H, H-1'), 3.86 (s, 3 H, 4-OCH₃), 3.79 (s, 3 H, 3-OCH₃), 2.79–2.74 (m, 2 H, H-1''), 2.65–2.59 (m, 2 H, H-5''), 2.20 (s, 3 H, H-3'), 1.69–1.56 (m, 4 H, H-2'', H-3''), 1.46–1.34 (m, 2 H, H-4'').

¹³C NMR (75 MHz, CDCl₃): δ = 202.0 (C-2''), 167.5 (ArCO₂CH₂), 154.3 (C-4), 144.0 (C_{ipso}), 142.9 (C-2), 141.9 (C-6), 133.2 (C-3), 128.5 (2 C, C_{ortho}),* 128.3 (2 C, C_{meta}),* 125.7 (C_{para}), 106.9 (C-1), 103.6 (C-5), 68.3 (C-1'), 59.8 (3-OCH₃), 55.8 (4-OCH₃), 36.0 (C-5''), 35.8 (C-1''), 32.0 (C-2''), 31.4 (C-4''), 29.5 (C-3''), 26.1 (C-3').

HRMS (ESI): m/z [M + H]⁺ calcd for C₂₃H₃₀NO₅: 400.2119; found 400.2105.

3,7,8-Trimethoxy-2-methyl-5-(5'-phenyl-1'-pentyl)quinoline-4(1H)-one (Melovinone, 2)

The anthranilate **33** (30.0 mg, 0.08 mmol) was weighed in a micro-wave vial and dissolved in glacial AcOH (1.0 mL). The system was purged with argon, capped, and irradiated at 150 °C (power = 60 W) for 25 min. The reaction was controlled by TLC, confirming complete consumption of the starting material and product formation by its characteristic fluorescence UV (360 nm), an orange spot after spraying with the Dragendorff–Munier reagent and an intense blue colored spot obtained after exposure to aq 1% FeCl₃ solution. Removal of the solvent under high vacuum gave the crude pseudane **34** as a solid, which was used for the next step without purification; yield: 29 mg (ca. 88%).

HRMS (ESI): m/z [M + H]⁺ calcd for C₂₃H₂₈NO₄: 382.2013; found: 382.2011.

Compound **34** (28.5 mg, 0.07 mmol) and K₂CO₃ (41.3 mg, 0.30 mmol) were suspended in anhyd 2-propanol (1.4 mL) contained in a screw capped tube. After purging with argon, the mixture was stirred for 15 min at rt, and further treated with MeI (95 μ L, 1.5 mmol). The reaction vessel was tightly closed and heated at 50 °C for 3.5 h. The reaction was then quenched with H₂O (5 mL) and the products were extracted with EtOAc (3 \times 10 mL). The combined organic phases were washed with brine (15 mL), dried (MgSO₄), and concentrated under vacuum. The remaining oily material was chromatographed to afford melovinone (**2**) as a white amorphous solid; yield: 10.8 mg (40% overall yield from anthranilate **33**); mp 130–128 °C (from EtOAc/EtOH ~9:1) (Lit.^{1b} mp 136–134 °C (from PE/benzene)).

IR (NaCl): 3414, 2935, 2918, 2839, 1618, 1560, 1526, 1420, 1319, 1250, 1138, 1005, 899, 746, 698 cm⁻¹.

¹H NMR (300 MHz, CDCl₃): δ = 8.11 (br s, $w_{1/2}$ = ~6.6 Hz, 1 H, NH), 7.29–7.12 (m, 5 H, C₆H₅), 6.61 (s, 1 H, H-6), 3.97 (s, 3 H, 8-OCH₃), 3.95 (s, 3 H, 7-OCH₃), 3.85 (s, 3 H, 3-OCH₃), 3.32 (dd, J = 6.2, 2.8 Hz, 2 H, H-1'), 2.60 (dd, J = 7.0, 1.9 Hz, 2 H, H-5'), 2.40 (s, 3 H, 2-CH₃), 1.73–1.60 (m, 4 H, H-2', H-4'), 1.56–1.46 (m, 2 H, H-3').

The ¹H NMR spectrum of **2** was in full agreement with that reported by Kapadia et al. for the natural product.^{1b}

¹³C NMR (75 MHz, CDCl₃): δ = 175.1 (C-4), 151.5 (C-7), 143.4 (C_{ipso}), 142.0 (C-5), 141.2 (C-3), 138.2 (C-2), 134.7 (C-8a), 132.7 (C-8), 128.6 (2 C, C_{ortho}), 128.3 (2 C, C_{meta}), 125.6 (C_{para}), 118.3 (C-4a), 110.4 (C-6), 61.2 (8-OCH₃), 59.8 (3-OCH₃), 56.2 (7-OCH₃), 36.2 (C-5'), 35.9 (C-1'), 32.2 (C-2'), 31.7 (C-4'), 29.8 (C-3'), 15.2 (2-CH₃).

HRMS (ESI): m/z [M + H]⁺ calcd for C₂₄H₃₀NO₄: 396.2169; found: 396.2164.

2'-Oxopropyl 3,4-Dimethoxy-2-nitro-6-(oct-1-yn-1-yl)benzoate (35)

A mixture of [Pd(PPh₃)₄] (6.5 mg, 0.009 mmol), CuI (1.64 mg, 0.008 mmol), and **25** (50 mg, 0.170 mmol) in anhyd DMF (2.0 mL) contained in a screw capped tube under argon was sequentially treated with Et₃N (100 mL, 0.715 mmol) and 1-octyne (36 mL, 0.210 mmol). The system was purged with an intense stream of argon for 1 min, screw capped, and placed in a preheated bath (70 °C) for 15 h. Then, the volatiles were removed under reduced pressure and the remaining oily residue was dissolved in EtOAc (10 mL) and filtered through a Florisil® pad, affording the crude coupling product **35**; yield: 53 mg (78%). This oily material was unstable to chromatographic conditions.

IR (NaCl): 2930, 2861, 2230, 1736, 1729, 1615, 1542, 1360, 1241, 1129, 820 cm⁻¹.

¹H NMR (300 MHz, CDCl₃): δ = 7.07 (s, 1 H, H-5), 4.72 (s, 2 H, H-1'), 3.94 (s, 3 H, 4-OCH₃), 3.93 (s, 3 H, 3-OCH₃), 2.39 (t, J = 7.2 Hz, 2 H, H-3''), 2.21 (s, 2 H, H-3'), 1.44–1.25 (m, 6 H, H-4'' to H-7''), 0.89 (t, J = 6.9 Hz, 3 H, H-8'').

¹³C NMR (75 MHz, CDCl₃): δ = 201.9 (C-2'), 162.7 (ArCO₂CH₂), 155.4 (C-4), 141.1 (C-2), 132.2 (C-3), 128.7 (C-6), 121.4 (C-1), 118.0 (C-5), 97.6 (C-2''), 77.3 (C-1''), 69.7 (C-1'), 62.6 (3-OCH₃), 56.7 (4-OCH₃), 31.4 (C-6''), 28.7 (C-5''), 28.4 (C-4''), 26.5 (C-3'), 22.6 (C-7''), 19.7 (C-3''), 14.1 (C-8'').

HRMS (ESI): m/z [M + Na]⁺ calcd for C₂₀H₂₅NO₇Na: 414.1523; found 414.1520.

2'-Oxopropyl 6-Allyl-3,4-dimethoxy-2-nitrobenzoate (36) and 2'-Oxopropyl (E)-3,4-Dimethoxy-2-nitro-6-(prop-1-en-1-yl)benzoate (37)

A mixture of bromoarene **25** (25 mg, 0.07 mmol), LiCl (11.7 mg, 0.280 mmol), Pd(Ph₃P)₄ (8.0 mg, 0.007 mmol), and allyltri(*n*-butyl)stannane (40 μ L, 0.140 mmol) in anhyd toluene (1.5 mL) contained in a screw capped tube was purged with argon for 5 min. The system was tightly closed with a screw cap and placed in a preheated oil bath at 80 °C for 18 h. Then, the mixture was diluted with EtOAc (5.0 mL) and filtered through Celite. The volatiles were removed under vacuum and the oily residue was chromatographed to give the allylbenzene derivative **36** as a clear oil; yield: 12.3 mg (92%).

¹H NMR (300 MHz, acetone-*d*₆): δ = 7.25 (s, 1 H, H-5), 5.96 (ddd, J = 16.8, 10.3, 6.5 Hz, 1 H, H-2''), 5.13 (dt, J = 10.3, 1.5 Hz, 1 H, H-3''_a), 5.09 (ddd, J = 16.8, 2.9, 1.5 Hz, 1 H, H-3''_b), 4.92 (s, 2 H, H-1'), 4.02 (s, 3 H, 4-OCH₃), 3.90 (s, 3 H, 3-OCH₃), 3.69 (dd, J = 6.5, 1.5 Hz, 2 H, H-1''), 2.19 (s, 3 H, 3-CH₃).

¹³C NMR (75 MHz, acetone-*d*₆): δ = 201.0 (C-2'), 164.4 (ArCO₂CH₂), 156.4 (C-4), 146.6 (C-2), 140.5 (C-3), 138.9 (C-6), 137.5 (C-2''), 117.1 (C-1), 117.0 (C-5),* 116.9 (C-3''), 70.2 (C-1'), 63.5 (3-OCH₃), 57.5 (4-OCH₃), 38.4 (C-1''), 26.0 (C-3').

HRMS (ESI): m/z [M + Na]⁺ calcd for C₁₅H₁₇NO₇Na: 346.0897; found: 346.0900.

When longer reaction times were used or simply after standing some time in solution, a mixture consisting by the allyl derivative and its isomerized by-product **37** was observed (**36**:**37** = ~10:1).

37

¹H NMR (300 MHz, CHCl₃): δ = 7.12 (s, 1 H, H-5), 6.86 (dq_b, *J* = 15.6, 1.7 Hz, 1 H, H-1''), 6.21 (dq, *J* = 15.6, 6.6 Hz, 1 H, H-2''), 4.77 (s, 2 H, H-1'), 3.97 (s, 3 H, 4-OCH₃), 3.92 (s, 3 H, 3-OCH₃), 2.20 (s, 3 H, H-3'), 1.93 (dd, *J* = 6.6, 1.7 Hz, 3 H, H-3'').

¹³C NMR (75 MHz, CDCl₃): δ = 201.0 (C-2'), 163.7 (ArCO₂CH₂), 155.5 (C-4), 140.0 (C-6), 134.3 (C-3), 131.1 (C-2''), 128.6 (C-2), 127.4 (C-1''), 116.5 (C-1), 111.3 (C-5), 69.7 (C-1'), 62.5 (3-OCH₃), 56.5 (4-OCH₃), 26.3 (C-3'), 18.8 (C-3'').

HRMS (ESI): *m/z* [M + Na]⁺ calcd for C₁₅H₁₇NO₇Na: 346.0897; found: 346.0900.

2'-Oxopropyl (E)-3,4-Dimethoxy-2-nitro-6-(5-phenylpent-2-en-1-yl)benzoate (39) and 2'-Oxopropyl (E)-3,4-Dimethoxy-2-nitro-6-(4-phenylbut-1-en-1-yl)benzoate (40)

Method A: A solution of allylbenzene derivative **25** (20.3 mg, 0.063 mmol) and 4-phenyl-1-butene (38 μL, 0.253 mmol) in anhyd toluene (1.0 mL) was purged with argon and treated with Grubbs II catalyst (2.7 mg, 0.003 mmol). The system was closed and heated at 40 °C for 6 h. Once the reaction was judged complete, the solution was filtered through a cotton plug, washed with CH₂Cl₂, and evaporated to dryness. The remaining oil was chromatographed affording an equimolar inseparable mixture of **39** and **40**; yield: 14.3 mg (53%).

39

¹H NMR (300 MHz, acetone-*d*₆): δ = 7.35–7.09 (m, 4 H, H_{ortho}, H_{meta}), 7.23 (s, 1 H, H-5), 7.18–7.11 (m, 1 H, H_{para}), 5.62 (m, 2 H, H-2'', H-3''), 4.90 (s, 2 H, H-1'), 3.97 (s, 3 H, 4-OCH₃), 3.89 (s, 3 H, 3-OCH₃) 3.60 (m, 2 H, H-1''), 2.68 (t, *J* = 7.2 Hz, 2 H, H-5''), 2.3 (m, 2 H, H-4''), 2.17 (s, 3 H, H-3').

¹³C NMR (75 MHz, acetone-*d*₆): δ = 201.1 (C-2'), 164.4 (ArCO₂CH₂), 156.3 (C-4), 146.5 (C-2), 142.7 (C-3), 139.6 (C_{ipso}), 132.8 (C-3''), 129.6 (C-6), 129.3 (2 C, C_{meta}), 129.0 (2 C, C_{ortho}, C-2''), 127.4 (C-1), 126.6 (C_{para}), 116.8 (C-5), 70.2 (C-1'), 62.5 (3-CH₃O), 57.1 (4-CH₃O), 37.1 (C-1''), 36.4 (C-5''), 35.0 (C-4''), 26.0 (C-3').

HRMS (ESI): *m/z* [M + Na]⁺ calcd for C₂₃H₂₅NO₇Na: 450.1523; found: 450.1518.

40

¹H NMR (300 MHz, acetone-*d*₆): δ = 7.45 (s, 1 H, H-5), 7.35–7.09 (m, 4 H, H_{ortho}, H_{meta}), 7.18–7.11 (m, 1 H, H_{para}), 7.02 (dt, *J* = 15.7, 1.5 Hz, 1 H, H-1''), 6.55 (m, 1 H, H-2''), 4.92 (s, 2 H, H-1'), 4.05 (s, 3 H, 4-OCH₃), 3.91 (s, 3 H, 3-OCH₃), 2.80 (br s, *w*_{1/2} = ~3.2 Hz, 2 H, H-4''), 2.52 (m, 2 H, H-3''), 2.17 (s, 3 H, H-3').

¹³C NMR (75 MHz, acetone-*d*₆): δ = 201.2 (C-2'), 164.4 (ArCO₂CH₂), 156.3 (C-4), 146.2 (C-2), 142.5 (C-3), 140.1 (C_{ipso}), 135.9 (C-2''), 130.0 (C-6), 129.5 (2 C, C_{meta}), 129.2 (2 C, C_{ortho}), 127.4 (C-1''), 126.7 (C_{para}), 126.6 (C-1), 112.3 (C-5), 70.3 (C-1'), 62.6 (3-CH₃O), 57.1 (4-CH₃O), 35.9 (C-4''), 35.7 (C-3''), 26.0 (C-3').

HRMS (ESI) *m/z* [M + Na]⁺ calcd for C₂₂H₂₃NO₇Na: 436.1367; found: 436.1356.

Method B: A solution of Hoveyda–Grubbs II catalyst (5.0 mg, 0.006 mmol) in CH₂Cl₂ (2.0 mL) was infused at 2.5 mL/h into a refluxing mixture of allylbenzene **36** (40 mg, 0.124 mmol), 4-phenyl-1-butene (37 μL, 0.248 mmol), and 1,4-benzoquinone (1.3 mg, 0.012 mmol) in

anhyd CH₂Cl₂ (2.0 mL). The mixture was further refluxed for 2.5 h. Once the reaction was completed, the solution was filtered through a cotton plug, the solids were washed with CH₂Cl₂, and the combined organic solutions were evaporated to dryness. The resulting oil was chromatographed, affording **39** and **40** as an inseparable mixture in a 1.8:1 molar ratio; yield: 50 mg (ca. 95%). The NMR spectra of **39** and **40** were in agreement with those of the product obtained after Method A.

Funding Information

The authors are indebted to Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (PUE-0006-2016) and Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT) (PICT 2014-0445 and PICT 2017-0149) for financial support. AAAA acknowledges CONICET for his Doctoral fellowship. The authors also wish to thank the Agencia Santafesina de Ciencia, Tecnología e Innovación Productiva (ASACTel) for an institutional grant (AC 2015-0005) to Instituto de Química Rosario (IQUIR) for acquisition of a 400 MHz spectrometer.

Supporting Information

Supporting information for this article is available online at <https://doi.org/10.1055/s-0039-1690164>.

References

- (1) (a) Kapadia, G. J.; Paul, B. D.; Silverton, J. V.; Fales, H. M.; Sokolowski, E. A. *J. Am. Chem. Soc.* **1975**, *97*, 6814. (b) Kapadia, G. J.; Shukla, Y. N.; Basak, S. P.; Fale, H. M.; Sokolowski, E. A. *Phytochemistry* **1978**, *17*, 1444.
- (2) (a) Hoelzel, S. C. S. M.; Vieira, E. R.; Giacomelli, S. R.; Dalcol, I. I.; Zanatta, N.; Morel, A. F. *Phytochemistry* **2005**, *66*, 1163. (b) Gressler, V.; Stüker, C. Z.; Dias, G. de O. C.; Dalcol, I. I.; Burrow, R. A.; Schmidt, J.; Wessjohann, L.; Morel, A. F. *Phytochemistry* **2008**, *69*, 994.
- (3) (a) Dias, G. C. D.; Gressler, V.; Hoelzel, S. C. S. M.; Silva, U. F.; Dalcol, I. I.; Morel, A. F. *Phytochemistry* **2007**, *68*, 668. (b) Emile, A.; Waikedre, J.; Herrenknecht, C.; Fourneau, C.; Gantier, J.-C.; Hnawia, E.; Cabalion, P.; Hocquemiller, R.; Fournet, A. *Phytother. Res.* **2007**, *21*, 398.
- (4) (a) Jang, J. Y.; Le Dang, Q.; Choi, Y. H.; Choi, G. J.; Jang, K. S.; Cha, B.; Luu, N. H.; Kim, J. C. *J. Agric. Food Chem.* **2015**, *63*, 68. (b) Jang, J. Y.; Le Dang, Q.; Choi, Y. H.; Choi, G. J.; Jang, K. S.; Cha, B.; Luu, N. H.; Kim, J. C. *J. Agric. Food Chem.* **2015**, *63*, 3803. (c) Jang, J. Y.; Dang, Q. L.; Choi, G. J.; Park, H. W.; Kim, J.-C. *Pest. Manag. Sci.* **2019**, *75*, 2264. (d) Wang, G. C.; Li, T.; Wei, Y.-R.; Zhang, Y.-B.; Li, Y.-L.; Sze, S. C. W.; Ye, W. C. *Fitoterapia* **2012**, *83*, 1643. (e) Jadulco, R. C.; Pond, C. D.; Van Wagoner, R. M.; Koch, M.; Gideon, O. G.; Matainaho, T. K.; Piskaut, P.; Barrows, L. R. *J. Nat. Prod.* **2014**, *77*, 183.
- (5) (a) Cretton, S.; Breant, L.; Pourrez, L.; Ambuehl, C.; Marcourt, L.; Ebrahimi, S. N.; Hamburger, M.; Perozzo, R.; Karimou, S.; Kaiser, M.; Cuendet, M.; Christen, P. *J. Nat. Prod.* **2014**, *77*, 2304. (b) Cretton, S.; Dorsaz, S.; Azzollini, A.; Favre-Godal, Q.; Marcourt, L.; Ebrahimi, S. N.; Voinesco, F.; Michellod, E.; Sanglard, D.; Gindro, K.; Wolfender, J.-L.; Cuendet, M.; Christen, P. *J. Nat. Prod.* **2016**, *79*, 300.

- (6) (a) Soekamto, N. H.; Liong, S.; Fauziah, S.; Wahid, I.; Firdaus Taba, P.; Ahmad, F. *J. Phys.: Conf. Ser.* **2018**, *979*, 012017. (b) Cretton, S.; Bréant, L.; Pourrez, L.; Ambuehl, C.; Perozzo, R.; Marcourt, L.; Kaiser, M.; Cuendet, M.; Christen, P. *Fitoterapia* **2015**, *105*, 55. (c) Simoben, C. V.; Ntie-Kang, F.; Akone, S. H.; Sippl, W. *Nat. Prod. Bioprospect.* **2018**, *8*, 151. (d) Monteillier, A.; Cretton, S.; Ciclet, O.; Marcourt, L.; Ebrahimi, S. N.; Christen, P.; Cuendet, M. *J. Ethnopharmacol.* **2017**, *203*, 214.
- (7) (a) Petit, C.; Ceccarelli, M.; Cretton, S.; Houriet, J.; Skalicka-Woźniak, K.; Christen, P.; Carrupt, P.-A.; Goracci, L.; Wolfender, J.-L. *Planta Med.* **2017**, *83*, 718. (b) Petit, C.; Bujard, A.; Skalicka-Woźniak, K.; Cretton, S.; Houriet, J.; Christen, P.; Carrupt, P.-A.; Wolfender, J.-L. *Planta Med.* **2016**, *82*, 424. (c) Zongo, F.; Ribout, C.; Boumendjel, A.; Guissou, I. *J. Ethnopharmacol.* **2013**, *148*, 14.
- (8) (a) Khamphaya W., Ngernmeesri P.; *Toward the total synthesis of anti-HIV waltherson C*; Proceedings of the 2016 Pure and Applied Chemistry International Conference (PACCON 2016), Bangkok, Thailand, February 9–11, 2016.; SYN-1113. (b) Mäkinen, M. E.; Mallik, R.; Siitonen, J. H.; Kärki, K.; Pihko, P. M. *Synlett* **2017**, *28*, 1209. (c) Arroyo Aguilar, A. A.; Bolívar Avila, S. J.; Kaufman, T. S.; Larghi, E. L. *Org. Lett.* **2018**, *20*, 5058. (d) Zdorichenko, V.; Paumier, R.; Whitmarsh-Everiss, T.; Roe, M.; Cox, B. *Chem. Eur. J.* **2019**, *25*, 1286.
- (9) (a) Cortés, I.; Borini Etichetti, C. M.; Girardini, J. E.; Bracca, A. B. J.; Kaufman, T. S. *Synthesis* **2019**, *51*, 433. (b) Pergomet, J. L.; Bracca, A. B. J.; Kaufman, T. S. *Org. Biomol. Chem.* **2017**, *15*, 7040. (c) Méndez, M. V.; Heredia, D. A.; Larghi, E. L.; Bracca, A. B. J.; Kaufman, T. S. *RSC Adv.* **2017**, *7*, 28298. (d) Pergomet, J. L.; Larghi, E. L.; Kaufman, T. S.; Bracca, A. B. J. *RSC Adv.* **2017**, *7*, 5242. (e) Simonetti, S. O.; Larghi, E. L.; Bracca, A. B. J.; Kaufman, T. S. *Org. Biomol. Chem.* **2012**, *10*, 4124.
- (10) (a) Pergomet, J. L.; Di Liberto, M. G.; Derita, M. G.; Bracca, A. B. J.; Kaufman, T. S. *Fitoterapia* **2018**, *125*, 98. (b) Simonetti, S. O.; Larghi, E. L.; Kaufman, T. S. *Org. Biomol. Chem.* **2016**, *14*, 2625. (c) Pergomet, J. L.; Kaufman, T. S.; Bracca, A. B. J. *Helv. Chim. Acta* **2016**, *99*, 398. (d) Heredia, D. A.; Larghi, E. L.; Kaufman, T. S. *Eur. J. Org. Chem.* **2016**, 1397.
- (11) Hartz, R. In *Name Reactions in Heterocyclic Chemistry II*; Li, J. J.; Corey, E. J., Ed.; Wiley: New York, **2011**.
- (12) Otto, N.; Ferenc, D.; Opatz, T. *J. Org. Chem.* **2017**, *82*, 1205.
- (13) (a) Chen, H.; Long, H.; Cui, X.; Zhou, J.; Xu, M.; Yuan, G. *J. Am. Chem. Soc.* **2014**, *136*, 2583. (b) Takaya, D.; Yamashita, A.; Kamijo, K.; Gomi, J.; Ito, M.; Maekawa, S.; Enomoto, N.; Sakamoto, N.; Watanabe, Y.; Arai, R.; Umeyama, H.; Honma, T.; Matsumoto, T.; Yokoyama, S. *Bioorg. Med. Chem.* **2011**, *19*, 6892.
- (14) (a) Raiford, L. C.; Stoesser, W. C. *J. Am. Chem. Soc.* **1928**, *50*, 2556. (b) Hazlet, S. E.; Lehman, J. Jr. *J. Org. Chem.* **1962**, *27*, 2139. (c) Sakamoto, T.; Miura, N.; Kondo, Y.; Yamanaka, H. *Chem. Pharm. Bull.* **1986**, *34*, 2760. (d) Raiford, L. C.; Floyd, D. E. *J. Org. Chem.* **1943**, *8*, 358.
- (15) CCDC 1911796 contains the supplementary crystallographic data for this paper. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/getstructures
- (16) (a) Molander, G. A. *J. Org. Chem.* **2015**, *80*, 7837. (b) Maluenda, I.; Navarro, O. *Molecules* **2015**, *20*, 7528. (c) Lennox, A. J. J.; Lloyd-Jones, G. C. *Chem. Soc. Rev.* **2014**, *43*, 412.
- (17) (a) Coulter, M. M.; Kou, K. G. M.; Galligan, B.; Dong, V. M. *J. Am. Chem. Soc.* **2010**, *132*, 16330. (b) Chen, C.; Dugan, T. R.; Brennessel, W. W.; Weix, D. J.; Holland, P. L. *J. Am. Chem. Soc.* **2014**, *136*, 945.
- (18) (a) Djellal, A.; Djerourou, A. *Phosphorus, Sulfur Silicon Relat. Elem.* **2004**, *179*, 1123. (b) Adams, J.; Behnke, M. L.; Castro, A. C.; Evans, C. A.; Grenier, L.; Grogan, M. J.; Liu, T.; Snyder, D. A.; Tibbitts, T. PCT Int. Appl WO 2008063300, **2008**; *Chem. Abstr.* **2008**, *149*, 10119
- (19) (a) Molander, G.; Ito, T. *Org. Lett.* **2001**, *3*, 393. (b) Vedejs, E.; Fields, S. C.; Hayashi, R.; Hitchcock, S. R.; Powell, D. R.; Schrimpf, M. R. *J. Am. Chem. Soc.* **1999**, *121*, 2460.
- (20) Cleaver, L.; Nimgirawath, S.; Ritchie, E.; Taylor, W. C. *Aust. J. Chem.* **1976**, *29*, 2003.
- (21) (a) Khurana, J. M.; Gogia, A. *Org. Prep. Proced. Int.* **2009**, *29*, 1. (b) Seltzman, H. H.; Berrang, S. D. *Tetrahedron Lett.* **1993**, *34*, 3083.
- (22) (a) Hradil, P.; Hlaváč, J.; Lemr, K. *J. Heterocycl. Chem.* **1999**, *36*, 141. (b) Hradil, P.; Grepl, M.; Hlaváč, J.; Sural, M.; Malon, M.; Bertolasi, V. *J. Org. Chem.* **2006**, *71*, 819. (c) Hodgkinson, J. T.; Galloway, W. R. J. D.; Saraf, S.; Baxendale, I. R.; Ley, S. V.; Ladlow, M.; Welch, M.; Spring, D. R. *Org. Biomol. Chem.* **2011**, *9*, 57.
- (23) (a) Marco-Contelles, J.; Pérez-Mayoral, E.; Samadi, A.; Carreiras, M. C.; Soriano, E. *Chem. Rev.* **2009**, *109*, 2652. (b) Hartz, R. In *Name Reactions in Heterocyclic Chemistry II*; Li, J. J.; Corey, E. J., Ed.; Wiley: New York, **2011**, 376–384.
- (24) Maurer, C. K.; Steinbach, A.; Hartmann, R. W. *J. Pharm. Biomed. Anal.* **2013**, *86*, 127.
- (25) Morel, A. F.; Larghi, E. L.; Manke Selvero, M. *Synlett* **2005**, 2755.
- (26) (a) Simonetti, S. O.; Larghi, E. L.; Kaufman, T. S. *Org. Biomol. Chem.* **2014**, *12*, 3735. (b) Su, W.; Urgaonkar, S.; Verkade, J. G. *Org. Lett.* **2004**, *6*, 1421. (c) Stille, J. K.; Groh, B. L. *J. Am. Chem. Soc.* **1987**, *109*, 813. (d) Echavarren, A. M.; Stille, J. K. *J. Am. Chem. Soc.* **1987**, *109*, 5478.
- (27) (a) Bennett, C. J.; Caldwell, S. T.; McPhail, D. B.; Morrice, P. C.; Duthie, G. G.; Hartley, R. C. *Bioorg. Med. Chem.* **2004**, *12*, 2079. (b) Lo, M.; Mahajan, D.; Wytko, J. A.; Boudon, C.; Weiss, J. *Org. Lett.* **2009**, *11*, 2487. (c) McLane, R. D.; Le Cozannet-Laidin, L.; Boyle, M. S.; Lanzillotta, L.; Taylor, Z. L.; Anthony, S. R.; Tranter, M.; Onorato, A. *J. Bioorg. Med. Chem. Lett.* **2018**, *28*, 334.
- (28) (a) Higman, C. S.; Plais, L.; Fogg, D. E. *ChemCatChem* **2013**, *5*, 3548. (b) Hong, S. H.; Sanders, D. P.; Lee, C. W.; Grubbs, R. H. *J. Am. Chem. Soc.* **2005**, *127*, 17160. (c) Bilel, H.; Hamdi, N.; Zagrouba, F.; Fischmeister, C.; Bruneau, C. *RSC Adv.* **2012**, *2*, 9584.
- (29) (a) Dash, J.; Arseniyadis, S.; Cossy, J. *Adv. Synth. Catal.* **2007**, *349*, 152. (b) Henkie, J. R.; Dhaliwal, S.; Green, J. R. *Synlett* **2012**, *23*, 2371.
- (30) Armarego, W. L. F.; Chai, C. L. L. *Purification of Laboratory Chemicals, 5th ed*; Butterworth-Heinemann: Oxford, **2003**.
- (31) Wagner, H.; Bladt, S.; Rickl, V. *Drug Analysis: A Thin Layer Chromatography Atlas*, 2nd ed; Springer: Heidelberg, **2009**, 360.
- (32) Sheldrick, G. M. *Acta Crystallogr., Sect. A* **2008**, *64*, 112.
- (33) (a) Adepu, R.; Prasad, B.; Ashfaq, M. A.; Ehtesham, N. Z.; Pal, M. *RSC Adv.* **2014**, *4*, 49324. (b) Martin, P. *Helv. Chim. Acta* **1989**, *72*, 1554.
- (34) Wang, C.; Wang, T.; Huang, L.; Hou, Y.; Lu, W.; He, H. *Arab. J. Chem.* **2016**, *9*, 882.